RJA
IRWD icon

Raymond James & Associates’s Ironwood Pharmaceuticals IRWD Stock Holding History

Raymond James & Associates’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-24,117
Closed -$303K – 4119
2022
Q1 		$303K Buy
24,117
+2,418
+11% +$27.7K ﹤0.01% 3409
2021
Q4 		$253K Buy
+21,699
New +$266K ﹤0.01% 3554

Other funds holding IRWD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Raymond James & Associates's IRWD Position: Q2 2022 in Review

Raymond James & Associates sold out of Ironwood Pharmaceuticals (IRWD) in Q2 2022, closing a stake of 24,117 shares — an estimated $303K sold.

Raymond James & Associates first reported a position in IRWD in Q4 2021 and held it in 2 quarters. The position peaked at $303K in Q1 2022. 239 funds tracked by Wall St. Rank hold IRWD as of Q2 2022.

  • Raymond James & Associates reported no remaining Ironwood Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Raymond James & Associates sold 24,117 Ironwood Pharmaceuticals shares in Q2 2022, an estimated $303K.
  • Raymond James & Associates first reported a position in Ironwood Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • Raymond James & Associates's Ironwood Pharmaceuticals position peaked at $303K in Q1 2022.
  • 239 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q2 2022.

Based on Raymond James & Associates's 13F filing for Q2 2022, filed 12 Aug 2022.